Parathyroid Hormone 1-84: Mechanism, Dosing & Research Data

Parathyroid hormone 1-84 (PTH 1-84, Natpara) is the full-length recombinant human parathyroid hormone, distinct from teriparatide which contains only the first 34 amino acids. It is FDA-approved for hypoparathyroidism as hormone replacement, the first and only drug approved to treat this condition by replacing the missing hormone rather than managing calcium/vitamin D levels alone.

Mechanism of Action

PTH1R activation (via N-terminal 1-34 sequence shared with teriparatide) drives cAMP/PKA signaling in kidney and bone
Renal tubular calcium reabsorption: PTH1R in distal tubule increases TRPV5 expression and active calcium reabsorption, raising serum calcium
Renal phosphate excretion: PTH inhibits NaPi2a/2c phosphate transporters in proximal tubule, lowering serum phosphate (key in hypoparathyroidism where phosphate is elevated)
Vitamin D activation: PTH stimulates renal 1-alpha hydroxylase, converting 25-OH vitamin D to 1,25-(OH)2 vitamin D; increases GI calcium absorption
C-terminal PTH (35-84) region may provide longer receptor engagement vs teriparatide, better mimicking endogenous PTH pulsatility

Research Findings

REPLACE trial: PTH 1-84 100 mcg every other day allowed 50% of hypoparathyroid patients to reduce or eliminate calcium/calcitriol supplementation vs 0% placebo
Osteosarcoma risk: lower risk signal than teriparatide in rodent high-dose/long-duration studies; hypoparathyroidism treatment does not require the black box warning restriction to 2 years
Natpara shortage/discontinuation: FDA extended availability but manufacturing challenges led to limited supply; affected patients switched to teriparatide (off-label for hypoPT)
Bone quality: hypoparathyroid patients treated with PTH 1-84 had improved bone microarchitecture and reduced cortical porosity vs conventional calcium/vitamin D treatment
Renal function preservation: PTH 1-84 reduced renal calcifications and preserved GFR better than conventional therapy in 5-year follow-up of REPLACE trial extension

Research Protocols

Hypoparathyroidism (FDA-approved): initiate at 50 mcg SC once daily; titrate by 25 mcg increments every 4 weeks based on serum calcium (target low-normal); maximum 100 mcg/day
Reduce calcium/calcitriol supplementation by 50% when starting; goal is to minimize supplementation while maintaining calcium in low-normal range
Monitor: serum calcium (2 weeks after each dose change), urine calcium, albumin, 25-OH vitamin D, phosphate
Research osteoporosis: 100 mcg SC 3x/week in postmenopausal women in comparison trials with teriparatide

Interactions

Calcium supplements: reduce as Natpara therapy progresses; over-supplementation causes hypercalcemia
Calcitriol (active vitamin D): reduce dose when starting Natpara; PTH 1-84 stimulates endogenous calcitriol synthesis
Thiazide diuretics: enhance renal calcium reabsorption; additive hypercalcemia risk with PTH 1-84; monitor closely

Safety Profile

FDA-approved for hypoparathyroidism. Hypercalcemia and hypocalcemia most common (dose-dependent); careful titration required. No 2-year treatment limit (unlike teriparatide). Available under REMS program due to osteosarcoma theoretical risk. Manufacturing supply challenges have limited availability since 2019.